The impact of a payer-provider joint venture on healthcare value

被引：0

作者：

Garabedian, Laura F. ^{[1
,2
]}

Wharam, J. Frank ^{[1
,2
,3
,4
]}

Newhouse, Joseph P. ^{[5
,6
,7
,8
]}

Lakoma, Matthew ^{[1
]}

Argetsinger, Stephanie ^{[1
]}

Zhang, Fang ^{[1
,2
]}

Galbraith, Alison A. ^{[9
,10
]}

机构：

[1] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Duke Univ, Dept Med, Durham, NC USA

[4] Duke Univ, Duke Margolis Ctr Hlth Policy, Durham, NC USA

[5] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA

[6] Harvard Kennedy Sch, Cambridge, MA USA

[7] Natl Bur Econ Res, Cambridge, MA USA

[8] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA

[9] Boston Med Ctr, Dept Pediat, Boston, MA USA

[10] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA

来源：

HEALTH SERVICES RESEARCH | 2024年

关键词：

health insurance; payer-provider joint venture; value-based payment; QUALITY; PERSPECTIVES; PERFORMANCE;

D O I：

10.1111/1475-6773.14400

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

ObjectiveTo examine how a novel payer-provider joint venture (JV) between one payer and multiple competitive delivery systems in New Hampshire (NH), which included value-based payment, care management, and non-financial supports, impacted healthcare value and payer and provider group experiences.Study Setting and DesignWe conducted a mixed-methods study. We used a quasi-experimental longitudinal difference-in-differences design to examine the impact of the JV (which started in January 2016 and ended in December 2020) on healthcare utilization, quality, and spending, using members in Maine (ME) as a control group. We also analyzed patient uptake of the JV's care management program using routinely collected administrative data and assessed payer and provider group leaders' perspectives about the JV via semi-structured interviews.Data Sources and Analytic SampleWe used administrative and claims data from 2013 to 2019 in a commercially insured population under 65 years in NH and ME. We also used administrative data on care management eligibility and uptake and conducted semi-structured interviews with payer and provider group leaders affiliated with the JV.Principal FindingsThe JV was associated with no sustained change in medical utilization, quality, and spending throughout the study period. In the first year of the JV, there was a $142 (95% confidence interval: $41, $243) increase in pharmaceutical spending per member and a 13% (4.4%, 25%) relative increase in days covered for diabetes medications. Only 15% of eligible members engaged in care management, which was a key component of the JV's multi-pronged approach. In a disconnect from the empirical findings, payer and provider group leaders believed that the JV reduced healthcare costs and improved quality.ConclusionsOur findings provide evidence for future payer-provider JVs and demonstrate the importance of having a valid control group when evaluating JVs and value-based payment arrangements.

引用

页数：10